RxDoctor Payments Data

Jeremy Campbell, DO

Family Medicine · Newark, OHNPI 1477533826

Payments from drug & device makers

$222in general payments, 2019–2025

Across 13 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$66
  • AbbVie$42
  • GSK$33
  • Dexcom, Inc.$23
  • Novo Nordisk$16
  • AstraZeneca$15
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$222 in reported general payments places this provider in the 40th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$301,554
Medicare patients
593
Services billed
7,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban655$338,883
TrulicityDulaglutide134$133,427
Enbrel SureclickEtanercept14$99,288
OzempicSemaglutide74$87,534
XareltoRivaroxaban136$78,630
JardianceEmpagliflozin100$71,400
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$65,046
NuplazidPimavanserin Tartrate12$63,688
Tresiba Flextouch U-100Insulin Degludec61$43,119
MounjaroTirzepatide36$42,845
Tresiba Flextouch U-200Insulin Degludec25$37,778
JanuviaSitagliptin Phosphate54$36,206
Breo ElliptaFluticasone/Vilanterol61$25,117
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog95$24,855
InvokanaCanagliflozin20$20,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$338,883655 claims
Novo NordiskOzempic, Rybelsus$16$98,82885 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$33$98,528192 claims
AstraZenecaFarxiga, Breztri Aerosphere$15$29,25841 claims
AbbVieLinzess$42$18,11918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Newark

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →